Adoram Therapeutics is developing a suite of therapies with an allosteric molecular mode of action, which can either positively or negatively modulate the signaling of specific GPCRs - the largest class of human receptors. Our foremost asset is a small molecule immunotherapy to treat patients with solid tumors. Thanks to its unique allosteric mode of action, this 3rd generation adenosine 2A receptor antagonist retains its potency in high adenosine (immunosuppressive) microenvironments, such as those found in many solid tumors, and is therefore intended to be used as a treatment for a wide range of cancers.
Location: Switzerland, Geneva, Lancy
Employees: 1-10
Founded date: 2022
Investors 2
| Date | Name | Website |
| 08.04.2023 | Venture Ki... | venturekic... |
| 25.03.2024 | VentureLab | venturelab... |
Mentions in press and media 3
| Date | Title | Description |
| 25.10.2024 | Three leading-edge Geneva Startups get FIF Funding | The awarded projects reflect Geneva’s strong ecosystem for fostering innovation in high-potential industries. Each project will benefit from funding to propel their products to the next stage of development. Seed loan awarded to Dyneo Tech... |
| 27.03.2024 | Ten startups on a business voyage in Boston | Selected from over 70 applications by a jury of investors and biotech experts, the ten startups selected for the 18th edition of Venture Leaders Biotech will join the roadshow in Boston, one of the world's most important life science hubs.... |
| 11.04.2023 | Startups leveraging allosteric biochemistry for cancer immunotherapy, using graphene for solar cells, delivering innovative protein technologies, providing a software to assist physiotherapists, and r... | Adoram Therapeutics: Leveraging allosteric biochemistry for patients Existing therapies are not efficacious in many types of solid tumors because of an immunosuppressive environment that is caused by a variety of factors, including high ade... |